ROVI updates its strategy in a meeting with shareholders, investors and analysts
Wed, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Related
Madrid: 28 of December 2022
The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (...
1 min
28/12/2022
Sustained-release drug delivery is a field where significant progress is being made that increases the efficacy of the medicines, improves...
3 min
24/11/2022
ROVI reports operating revenue growth of 24% and EBITDA growth of 25%
• Operating revenue increased by 24% to 575.5 million euros driven...
3 min
04/11/2022
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.